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FROM BACTERIA TO HUMANS: THE CRISPR/CAS9 EDITING SYSTEM, A 
NOVEL THERAPEUTIC  
 
SARAH L. MILLMAN 
ABSTRACT 
 CRISPR (clustered regulatory interspaced short palindromic repeats) is a bacterial 
adaptive immune system, which can target specific sequences of foreign nucleic acids.  
The system is made up of unique spacer sequences flanked by short, repetitive, 
palindromic sequences, and sequences encoding Cas (CRISPR associated) proteins.  The 
CRISPR-Cas9 system has been utilized from S. pyrogenes for use in eukaryotes for gene 
editing.  Many years were spent uncovering the components of the system and its 
mechanism.  Now the RNA-guided endonuclease abilities of the system are utilized to 
induce double-strand breaks in targeted DNA sequences.  Through the advent of double-
strand breaks researchers can now induce mutations, knock out genes through non-
homologous end joining, and knock-in DNA sequences through homologous directed 
repair.  Additionally, the system has been utilized in gene regulation to activate or repress 
protein expression.   
Studies have shown that CRISPR-Cas9 as a gene-editing tool is highly efficient 
and specific.  The system only requires a Cas9 protein and guideRNA to function and can 
alter multiple genes with the addition of different guideRNA.  Most scientists have 
reported minimal off-target mutations caused by Cas9, and many strategies have been 
initiated to reduce off-target effects even further.  Already, the system has been shown to 
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have therapeutic applications both in vitro in human cells and in vivo in animals 
(including non-human primates).  Future applications in therapeutics and gene-editing 
have the potential to change research and medicine. 
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INTRODUCTION 	  
 The first time scientists developed the ability to manipulate DNA occurred in the 
1970s with the advent of recombinant DNA technology (Hsu, Lander, & Zhang, 2014).  
More recent advances in genome engineering tools have allowed both molecular 
biologists and geneticists to make advances beyond creating novel therapeutics.  Now, 
researchers can directly alter the endogenous DNA of almost any organism, giving 
investigators the ability to study phenotypic traits based on genetics and alter the human 
genome—potentially curing genetic diseases (Barrangou, 2014; Hsu et al., 2014).  Some 
of the more recent advances in genetic engineering occurred with the advent of 
meganucleases, zinc finger nucleases (ZFNs) and transcription activator-like effector 
nucleases (TALENs), which are DNA binding proteins that induce double-strand breaks 
(DSBs) in DNA (Pâques & Duchateau, 2007; Strauss & Lahaye, 2013).  These proteins 
are often referred to as designer nucleases since they can be programmed to make DSBs 
at specific DNA sequences (Strauss & Lahaye, 2013).  Once a DSB has been induced, 
mutations can occur through endogenous repair called non-homologous end joining 
(NHEJ), or exogenous DNA can be incorporated into the genome through homologous 
directed repair (HR) (Kim & Kim, 2014).  The most current and rapidly developing 
designer nucleases is the CRISPR/Cas9 system, which has easily become the most 
promising advance in genome engineering (Hsu et al., 2014). 
 CRISPR (clustered regulatory interspaced short palindromic repeats) is a bacterial 
adaptive immune system, which can target specific sequences of foreign nucleic acids 
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(Hsu et al., 2014).  The system is made up of unique spacer sequences flanked by short, 
repetitive, palindromic sequences that form a CRIPSR array, and sequences encoding Cas 
(CRISPR associated) proteins (Kim & Kim, 2014).  Currently, there are three identified 
types of CRISPR-Cas systems (Chylinski, Makarova, Charpentier, & Koonin, 2014), 
however the type II system, known as CRISPR-Cas9, has been utilized for genetic 
engineering due to its ease of use and minimal system components (Yingze Zhao, Ying, 
& Wang, 2014).  Figure 1 shows the components of the type II CRISPR-Cas9 system.  In 
order to understand its applicability in eukaryotic genome editing and superiority over 
other systems, one must look at the function of CRISPR-Cas9 systems in bacteria. 
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Figure 1.  Components of the CRISPR-Cas9 system.  The four components required 
for Cas9 to cleave a targeted DNA sequences are highlighted.  The Cas9 protein, seen 
here as a rounded object around the other components, is required to cut DNA.  The 
guideRNA is shown in red.  The hairpin loop, seen above, mimics the connection 
between tracrRNA and crRNA.  There are about 20 nucleotides of complementarity 
between the guideRNA and target DNA.  The targetDNA is a sequence of nucleotides 
that is adjacent to PAM and cleaved by Cas9.  The PAM sequence is recognized by Cas9 
and required for binding and cleavage.  Image from Broad Communications, 2014. 
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Type II CRISPR-Cas9 System in Prokaryotes 
 The CRISPR-Cas9 system in prokaryotes provides an adaptive immune 
mechanism to prepare for future invasions of phages or plasmids.  New spacers are added 
to the CRISPR array in an adaptive manner (Sampson & Weiss, 2014).  The proposed 
adaptive mechanism is that Cas1 and Cas2 proteins read an invading DNA sequence and 
incorporate it into the CRISPR array where it becomes a spacer.  If and when the same 
invasive species is encountered, the bacteria and its subsequent generations are able to 
target the foreign nucleic acids efficiently (Sampson & Weiss, 2014). 
 The molecular mechanism of the CRISPR-Cas9 system has been clearly 
elucidated over the past 5 years (Sampson & Weiss, 2014).  First, the crRNA array and 
tracrRNA in bacterial DNA is transcribed (Sampson & Weiss, 2014).  tracrRNA 
hybridizes with pre-crRNA which is then processed into crRNA with endogenous RNase 
III.  The mature crRNA and tracrRNA hybrid then forms a complex with Cas9 and guide 
the nuclease to the target DNA (Jinek et al., 2012).  RNA allows Cas9 to target specific 
DNA sequences since each crRNA nucleotide sequence is complementary to the target 
DNA (Figure 2) (Sampson & Weiss, 2014).   
 An essential aspect of the mechanism is the presence of the PAM sequence next 
to the target DNA site.  PAM prevents Cas9 from binding to direct repeats in the 
endogenous bacterial DNA sequence, allowing the system to distinguish the difference 
between its own DNA and invasive DNA (Hsu et al., 2014).  Evidence also indicates that 
PAM recognition aids in triggering Cas9 a conformation change from target binding to 
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DNA cleaving (Hsu et al., 2014).  After this conformational change, Cas9 cleaves target 
DNA three base pairs upstream of the PAM sequence (Hsu et al., 2014).   
  Type II CRISPR-Cas9 systems have also been identified as regulators of bacterial 
virulence (Louwen, Staals, Endtz, van Baarlen, & van der Oost, 2014).  This was first 
observed in Francisella novicida.  Bacterial lipoprotein (BLP) levels in the bacterial cell 
membrane inversely correlate with bacterial cell survival in a host macrophage so that 
when BLP levels are high the bacterial survival decreases (Louwen et al., 2014).  
Bacterial virulence originates from CRISPR-Cas9 system regulation of bacterial BLP 
levels (Sampson & Weiss, 2014).  To increase bacterial survival, CRISPR-Cas9 can act 
to decrease BLP mRNA.  Complementary crRNA to BLP mRNA allow Cas9 to bind to 
and degrade BLP mRNA (Louwen et al., 2014).  This Cas9 action on BLP mRNA is 
activated once bacterial cells are attacked by host macrophages in order to increase 
bacterial survival.  By increasing bacterial survival in a host, CRISPR-Cas9 adds to the 
pathogenicity of the bacteria by allowing it to evade a host’s immune system (Louwen et 
al., 2014).   
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Figure 2.  CRISPR-Cas9 function in prokaryotes.  The Cas9-crRNA-tracrRNA ternary 
complex scans phage DNA until it finds the proto-spacer sequence and PAM (Gasiunas, 
Sinkunas, & Siksnys, 2014).  The crRNA basepairs with complementary phage DNA and 
Cas9 degrades the DNA.  Figure adapted from Hsu et al., 2014; van der Oost et al., 2014. 
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Structure and Function of Cas9 
 Cas9, the central type II Cas protein, has been studied extensively.  The crystal 
structure of Cas9 was determined using x-ray crystallography in 2014 (Figures 3, 4) 
(Jinek et al., 2014).  The original study examined the structure of Cas9 from S. pyrogenes 
and A. naeslundii and determined that the Cas9 enzyme family is composed of a 
molecule with two nuclease lobes (Jinek et al., 2014).  One lobe is a nuclease lobe 
containing a HNH and RuvC domains, which cleave the complementary and non-
complementary target DNA strand, respectively (Nishimasu et al., 2014).  The nuclease 
lobe also contains a carboxy-terminal domain that interacts with the PAM sequence 
(Nishimasu et al., 2014).  The other lobe is a target recognition lobe, which is also 
referred to as the α-helical lobe (Jinek et al., 2014; Nishimasu et al., 2014).  Each lobe 
has a cleft that likely function in nucleic acid binding.  Once guideRNA binds to Cas9 
there is a significant conformational rearrangement resulting in a central channel where 
DNA binds (Jinek et al., 2014)  Figure 4 shows two depictions of the Cas9 protein 
structure in complex with both targetDNA and guideRNA.  
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Figure 3.  Cas9 crystal structure.  The helical lobe is shown in grey. The nuclease lobe 
is shown in yellow, red, blue, and pink.  The HNH domain is represented in yellow and 
the RuvC domain in blue.  The nuclease lobe cleft is depicted with an orange line.  The 
helical lobe cleft is shown as a dashed, black line.  Figure from Jinek et al., 2014. 
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Figure 4.  Cas9 structure with sgRNA and target DNA.  A) Looped structure of Cas9 
protein in complex with target DNA and sgRNA.  B) Surface structure of Cas9 protein in 
complex with target DNA and sgRNA.  The active sites of the two nuclease domains are 
circled with a dashed, yellow line.  The HNH domain is shown in pink and the RuvC 
domain is depicted as light blue (Nishimasu et al., 2014).  Figure from Nishimasu et al., 
2014. 
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Other Cas9 Proteins 
 Type II CRISPR-Cas9 is not the only type of CRISPR-Cas that exists in bacteria.  
There are three major types of CRISPR-Cas systems (Chylinski et al., 2014).  The shared 
characteristics of all three types is the ability to acquire new spacers and at least one Cas 
protein guided by RNA that binds to RNA or DNA and acts as an endonuclease (Bikard 
& Marraffini, 2013).  All three types encode Cas1 and Cas2 proteins, however, each type 
has one unique Cas protein.  Cas3, Cas9, and Cas10 belong to types I, II, and III, 
respectively (Zhang, Doak, & Ye, 2014).   
 Looking at Types I and III (Figure 4) it is clear that there are many more proteins 
required for theses system types to function (van der Oost et al., 2014).  Type II CRISPR-
Cas systems are considered the most minimal of the three and require the least number of 
components: a CRISPR repeat spacer array, three to four Cas genes, trans-activating 
crRNA (tracrRNA) and endogenous RNase III (Chylinski et al., 2014).  Type II CRISPR-
Cas9 systems are considered the easiest and most promising for use in genetic 
engineering (Yingze Zhao et al., 2014).  The difference between the three main types are 
highlighted in Figure 5 below. 
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Figure 5.  Diversity of CRISPR-Cas systems.  The Cas proteins are divided into 
categories based on their function.  The three main types of CRISPR systems utilize Cas1 
and Cas2 proteins when acquiring new spacers.  Type I and III use Cas6 or a variation of 
Cas6 (Cas6e) to process crRNA, whereas RNase III serves the same function in type II 
systems.  Cas9 is the only Cas protein utilized in addition to Cas1 and Cas2 for type II 
systems.  Types I and II use a multiple proteins for crRNA processing, assembly and 
surveillance, and target degradation.  Cas 3 is the unique protein in type I, Cas9 is the 
unique protein in type II, and Cas10 is the unique protein in type III.  Types I-A, I-E, II, 
and III-A interfere with DNA, whereas type III-B interferes with RNA. . Figure adapted 
from van der Oost et al., 2014. 
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From Bacteria to Humans 
 A series of discoveries occurred that allowed researchers to first uncover how the 
CRISPR-Cas9 system functions, determine the Cas9 endonuclease capabilities, and then 
figure out how to reapply the system in humans.  The first recorded recognition of repeat 
CRISPR sequences occurred in 1987.  A group of scientists from Japan noted the 
presence of these sequences while studying E. coli (Hsu et al., 2014).  The group 
published an article in the Journal of Bacteriology summarizing their investigation of the 
iap gene, stating: 
 An unusual structure was found in the 3’ –end flanking region of iap.  
Five highly  homologous sequences of 29 nucleotides were 
arranged as direct repeats with 32  nucleotides as spacing (Ishino, 
Shinagawa, Makino, Amemura, & Nakata, 1987). 
 
 
Ishino et al. noticed that repeat sequences were arranged in an array with spacer 
sequences in the genome of E. coli before anyone had discovered the function of these 
genes.  In fact, it wasn’t until the year 2000 that these sequences were classified as a 
family of clustered repeat elements (Hsu et al., 2014).  A paper by Mojica et al. referred 
to the repeats as short regularly spaced repeats (SRPR), noting their presence in 90% of 
archaea and over 40% of sequenced bacterial genomes (Mojica, Díez-Villaseñor, Soria, 
& Juez, 2000).  
 Again, some time passed before another CRISPR breakthrough transpired.  In 
2002 the term, “CRISPR,” was first used to describe the family of SRPRs in an article 
published in Molecular Biology.  Authors, Ruud Jansen et al. wrote,  
“To appreciate their characteristic structure, we will refer to this family as 
the clustered regularly interspaced short palindromic repeats (CRISPR),” 
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officially naming the 1987 discovery (Jansen, Embden, Gaastra, & 
Schouls, 2002).   
 
Jansen and company also fittingly named the sequences associated with the CRISPR 
repeats and spacers—CRIPSR-associated (Cas) genes (Hsu et al., 2014).   
 Three years later, the same group who first recognized CRISPR loci were present 
throughout the prokaryotic genome, proposed that the system functioned as an adaptive 
immune response in prokaryotes.  Mojica et al. noticed that CRISPR spacers matched 
pre-existing sequences within the genetic material of phages and plasmids and explained 
that CRISPR-RNA molecules could act as regulatory units that recognize targets through 
homology of the spacer sequence with interfering plasmid DNA (Mojica, Díez-
Villaseñor, García-Martínez, & Soria, 2005).  Another group proposed the same adaptive 
immune function around the same time (Pourcel, Salvignol, & Vergnaud, 2005).  These 
postulations were strongly supported by evidence published in previous studies showing 
that CRISPR loci are transcribed, generating anti-sense RNA that can inhibit phage 
proliferation (Bolotin, Quinquis, Sorokin, & Ehrlich, 2005; Hsu et al., 2014).   
 The first experimental evidence that CRISPR can acquire resistance to viruses 
came from work with a yogurt bacterial strain at the food company Danisco (Hsu et al., 
2014).  Barrangou, an investigator at the company, showed that after exposure to a virus, 
bacteria incorporated new spacers that were homologously derived from the virus 
(Barrangou et al., 2007).  With this discovery, and several others that rapidly followed, 
the mechanism of CRISPR defense was finally elucidated (Hsu et al., 2014).  One such 
discovery was the breakthrough finding that CRISPR interferes directly with target DNA 
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(Marraffini & Sontheimer, 2008). Marraffini and Sotheimer came to this conclusion 
when they observed that Type III CRISPR interference occurs only when an intact target 
sequence is present, but not when intact mRNA is present alone (Marraffini & 
Sontheimer, 2008). Another key finding in the path to uncovering the CRISPR 
mechanism came when researchers studying Type I CRISPR genes in E. coli noticed 
CRISPR genes were transcribed and then cleaved.  The researchers called the cleaved 
products small CRISPR-RNA (crRNA) and the precursor molecule pre-crRNA (Brouns 
et al., 2008).   
 At this point, research in the CRISPR field accelerated (Hsu et al., 2014).  Motifs 
were discovered next to the homologous spacer region of phage genetic material (Hsu et 
al., 2014).  In a 2008 article published by Helene Deveau and colleagues, these regions of 
spacer homology in phages were coined, proto-spacers.  The article states, “…the 
homologous spacer region in the phage genome, which we propose to name proto-spacer, 
was analyzed” (Deveau et al., 2008).  Additionally, the authors of the article proposed 
that a motif sequence present next to the phage proto-spacer is important for phage 
resistance (Deveau et al., 2008).  Building off of this observation, Marraffini and 
Sontheimer investigated the role of these “protospacer adjacent motifs” (PAMs) in self 
verses non-self discrimination of phage target DNA and CRISPR loci of the bacterial 
host genome (Marraffini & Sontheimer, 2010).  Until then, researchers knew that crRNA 
is transcribed from the CRISPR locus and then binds to plasmid DNA—but it was 
unclear what prevented crRNA from base-pairing with CRISPR locus from which it was 
encoded (Marraffini & Sontheimer, 2010).  Marraffini and Sontheimer proposed the that 
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PAM sequence, present only on target plasmid DNA, helped distinguish which sequence 
to bind to (Marraffini & Sontheimer, 2010). 
 Around the same time, scientists started apply the natural CRISPR system for 
biotechnology.  Such uses included producing phage-resistant dairy cultures and 
classifying bacteria (Hsu et al., 2014).  Two more key discoveries happened before 
genome editing with the type II CRISPR system was approached.  The first study, 
showed that Cas9 (previous called Cas5) has endonuclease activity and is able to cleave 
both plasmid and bacteriophage DNA within the proto-spacer region (Garneau et al., 
2010).  The second discovery uncovered a significant step in the maturation of crRNA 
(Hsu et al., 2014).  Researchers uncovered abundantly transcribed RNA that had 24-25 
nucleotides complementary to all  pre-crRNA (Deltcheva et al., 2011).  They called the 
transcripts trans-activating CRISPR RNA (tracrRNA) and noted that pre-crRNA 
maturation requires binding to tracrRNA, and the presence of RNase III and Cas9 
(Deltcheva et al., 2011).   
 With all of the components for the CRISPR-Cas9 system uncovered, scientists 
began to consider the applicability of Cas9 for genetic engineering (Hsu et al., 2014).  On 
the path to harnessing the type II CRISPR system as a gene-editing tool, Sapranauskas 
and colleagues transferred a CRISPR locus from S. thermophiles into E. coli. The article 
they published in 2011 showed that it is possible to express a functional CRISPR-Cas9 
system from one bacteria strain to prevent plasmid transformation in a different strain 
(Sapranauskas et al., 2011).  
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 One more essential article was published before CRISPR-Cas9 was used to target 
DNA in mammalian cells (Hsu et al., 2014).  Jinek and others published a paper 
highlighting the ability to program Cas9 for site-specific DNA cleavage using a single 
chimeric guideRNA instead of the biological tracrRNA and crRNA components (Jinek et 
al., 2012).  The chimeric guideRNA imitated the respective roles of tracrRNA and 
crRNA in facilitating DNA cleavage and guiding Cas9 to the target DNA (Jinek et al., 
2012).  Jinek at al. wrote that using an engineered, chimeric RNA a new programmable 
RNA-guided endonuclease could be used and provided great promise for future uses in 
gene-targeting and gene-editing applications (Jinek et al., 2012).  One year after this 
critical paper was published, as predicted, two different studies showed that type II 
CRISPR systems could be used to edit mammalian genomes (Hsu et al., 2014).   
 Since then, the system has been used in a variety of species including, cultured 
human cells (Maggio et al., 2014) medaka (Ansai & Kinoshita, 2014), bombyx mori (Liu 
et al., 2014), caenorhabditis elegans (Waaijers & Boxem, 2014), drosophila (Beumer & 
Carroll, 2014), xenopus tropicalis (Guo et al., 2014), and zebrafish (Auer & Del Bene, 
2014). Figure 5 below highlights the most important publications in the discovery of the 
type II CRISPR-Cas9 system.  From the rapid research and discovery to its already vast 
applications, one can start to see how truly exciting this new technology has become.   
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Figure 6.  Significant publications in the discovery of the type II CRISPR-Cas9 
system.  Highlights the major publications that contributed to the discovery of type II 
CRISPR-Cas9 systems beginning in 1987 and ending in 2014.  Figure adapted from Hsu 
et al., 2014. 
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Reapplying the CRISPR-Cas9 System in Eukaryotes 
 The most commonly used Cas9 protein for gene editing is from S. pyogenes (Hsu 
et al., 2014).  This is because the PAM sequence for S. pyrogenes Cas9 (SpCas9) has 
been studied extensively (Esvelt et al., 2013).  Targeting using this Cas9 can be achieved 
with both chimeric guideRNA (single guide RNA) or dual crRNA and tracrRNA (Hsu et 
al., 2014).  The chimeric guideRNA is 39 to 40 nucleotides long with a target recognition 
sequence at the 5’ end made up of about 20 nucleotides (Xu, Li, Van Nostrand, He, & 
Zhou, 2014).  The guideRNA takes on hairpin loop structure to mimic the interaction 
between crRNA and tracrRNA (Xu et al., 2014).  In order to induce genome engineering 
in eukaryotes, both Cas9 and engineered guideRNA must be expressed simultaneously 
(Xu et al., 2014).  Figure 6 shows the four components of the CRISPR-Cas9 system that 
are required for gene editing in eukaryotes.  
 After Cas9 and guideRNA are co-expressed in a cell, the first step in gene editing 
is using the CRISPR-Cas9 system is inducing a double strand break (DSB) in DNA 
through the endonuclease activity of Cas9.  Two endogenous repair pathways in the cell 
can result after a DSB is introduced into the genome: non-homologous end joining 
(NHEJ) and homology directed repair (HDR) (Sander & Joung, 2014).  NHEJ is a highly 
error prone system than can result in mutations by inserting or deleting nucleotide 
fragments and lead to frame-shift mutations during translation (Sander & Joung, 2014).  
Using HDR, specific sequences can be inserted into the DSB by inserting an exogenous 
DNA fragment with homology arms matching the nucleotide sequences on both sides of 
the break.  The sequence between the homology arms serves as a template for new 
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nucleotides to be added that are complementary to the exogenous sequence (Lattime & 
Gerson, 2014).  Figure 7 depicts the two repair pathways and their applications in gene 
editing. 	  
	  
	  
Figure	  7.	  Gene	  editing	  with	  CRISPR-­‐Cas9.	  	  After	  a	  Cas9-­‐induced	  DSB,	  NHEJ	  and	  HDR	  can	  occur.	  	  NHEJ	  results	  in	  deletions	  and	  insertions	  of	  nucleotides	  of	  variable	  length.	  	  Alternatively,	  HDR	  can	  add	  specific	  gene	  sequences	  at	  the	  site	  of	  the	  DSB	  using	  a	  donor	  DNA	  fragment	  that	  serves	  as	  a	  template	  for	  repair	  (Sander	  &	  Joung,	  2014).	  	  Figure	  from	  Sander	  &	  Joung,	  2014.	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Other gene editing tools, including ZFNs and TALENs, can also be engineered to 
target specific DNA sequences and produce DSBs (Mao et al., 2013).  Engineering new 
ZFN of TALEN proteins, however, requires a great deal of time and money.  Additional 
problems involve off-target cleavage, size and cytotoxicity (Carlson, Fahrenkrug, & 
Hackett, 2012).   Off-target effects and cytotoxicity seen with ZFNs are both high and 
mutagenesis efficiencies are low (Kim & Kim, 2014) TALENs on the other hand have 
high efficiency but can be over 1,200 amino acids long and delivery into cells can often 
serve as a challenge (Carlson et al., 2012; Kim & Kim, 2014).  CRISPR-Cas9-mediated 
DSBs result in high mutation rates with low cytotoxicity and variable to low off-target 
effects (Carlson et al., 2012). 
 Off-target effects have been reduced in CRISPR-Cas9 by altering the Cas9 
protein to act as a nickase that cleaves only one DNA strand (Kim & Kim, 2014).  The 
Cas9 nickase is useful in gene editing by adding a nick that can be repaired through 
HDR.  The mutant protein can also be used with two guideRNAs complementary to 
opposite sides of the target sequence to produce paired nicks for gene editing via both 
NHEJ and HDR pathways (Xu et al., 2014).   
 Just as CRISPR-Cas has gene regulating abilities in bacteria through 
destabilization of BLP mRNA (Louwen et al., 2014), it can also be used for gene 
regulation in eukaryotes.  A dCas9 (enzymatically inactive Cas9), with mutations in both 
RuvC and HNH nuclease domains, has applications in gene regulation through 
transcriptional control (Fineran & Dy, 2014).  Inactivated dCas9 in combination with a 
guideRNA can bind to target DNA, but does not act as an endonuclease and cleave DNA 
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(Xu et al., 2014).  Instead, dCas9 can be fused with activator or repressor proteins to 
increase or silence expression of a gene, respectively by bringing the fused proteins into 
proximity of a gene promoter (Prashant Mali, Esvelt, & Church, 2013).  The mutated 
dCas9 protein can also bind to DNA at transcriptional promoter sites and competitively 
block either elongation or initiation of transcription (Xu et al., 2014) 
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Specific Aims/Objectives 
 The CRISPR-Cas9 technology is widely becoming known as the superior gene 
editing technology to date.  Researchers have already used the system to alter endogenous 
genes in a number of organisms that are typically difficult to genetically modify.  Its 
efficiency and ease of use are indisputable.  While the CRISPR-Cas9 technology has 
unquestionable potential to stimulate development of new disease therapeutics, there are 
multiple challenges with the system that must be addressed before it can be used broadly 
in a therapeutic setting.  These include: Off-target effects, potential immunogenicity, 
finding a delivery modality, establishing guideRNA requirements, and finding a Cas9 
with a PAM able to recognize any part of the genome. 
 The goals of the present study are to specifically: 
1. Show that the CRISPR-Cas9 system has the ability to alter genes of 
multiple organisms and cell types 
2. Use experimental evidence to define the strengths of the system: 
efficiency, multiplexing, and ease of use 
3. Provide evidence that off-target effects can be reduced to negligible levels 
and summarize strategies that have been used thus far to eliminate off-
target effects 
4. Offer potential therapeutic approaches in humans based on in vivo 
experiments in animals and in vitro experiments using human cells and 
explain obstacles to therapeutic approaches 
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 It is expected that the evidence outlined in the present study will confirm the 
CRISPR-Cas9 system as an effective and superior gene-editing tool and help to eliminate 
doubts about potential off-target effects.   
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LITERATURE REVIEW 
 
Double-Strand Break Frequency vs. Other Systems 
 Like other designer nucleases, the CRISPR-Cas9 system can be used to induce 
DSBs and single-stranded breaks that can be repaired through NHEJ and HDR and to 
regulate gene expression (Sander & Joung, 2014; Strauss & Lahaye, 2013).  Through 
NHEJ insertions and deletions can cause mutations and alter an organism’s genome 
(Sander & Joung, 2014).  NHEJ induced mutations can lead to knock out of a gene (Horii 
et al., 2014).  One example of this is an experiment targeting the Tet1 gene—a gene 
encoding Tet proteins, which are essential in the DNA methylation process.  In the 
experiment, mice were co-transfected with Cas9 and Tet1-targeting guideRNA (Horii et 
al., 2014).  After analysis by electrophoresis, the knock out efficiency was determined to 
be 55% (Horii et al., 2014).  In other cases, NHEJ can lead to indel (insertion and 
deletion) mutations (Ansai & Kinoshita, 2014).  An experiment in medaka embryos 
produced 100% mutagenesis efficiencies for a guideRNA targeting the DJ-1 gene (Ansai 
& Kinoshita, 2014).  Using different guideRNAs produced varying frequencies of 
mutations ranging from 44.8% to 91.3% indicating that different guideRNAs are more 
efficient at producing mutations than others (Ansai & Kinoshita, 2014).   
 Mutagenesis efficiency is also dependent on guideRNA concentration.  One 
example experiment in zebrafish resulted in high indel mutation rates that varied between 
10.0% and 52.7% for different concentrations of guideRNA.  In the experiment, a 
guideRNA and an mRNA encoding the Cas9 protein were inserted into one-cell stage 
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zebrafish embryos via a microinjection method (Hwang et al., 2013a).  The highest 
frequencies of mutagenesis occurred with a solution of 12.5ng/µg guideRNA and 
200ng/µg Cas9 mRNA (Hwang et al., 2013a).  A similar study in Xenopus tropicalis 
conferred these findings (Guo et al., 2014).  When the concentrations of guideRNA were 
increased from 50pg/embryo to 500pg/embryo, the rate of mutagenesis went from 31.3% 
to 100% (Guo et al., 2014).   
 Gene knock-in is also possible with the CRISPR-Cas9 system through HDR 
(Beumer & Carroll, 2014).  Researchers have utilized the system’s ability to induce 
targeted gene knock-in by injecting a donor oligonucleotide DNA strand with Cas9 and 
guideRNA.  Knock-in frequencies in one example were low, between 3.5% and 15.6% 
(Hruscha et al., 2013).  An experiment in human cells resulted in equally low HDR rates.  
This experiment yielded rates between 3% and 8% (P. Mali et al., 2013).  Other 
experiments have demonstrated higher HDR events.  Rates reaching over 45% were 
observed in Toxoplasma gondii (Shen, Brown, Lee, & Sibley, 2014).  The highest rates or 
gene insertion in this experiment were observed with guideRNAs targeting the UPRT 
gene.  UPRT-targeting guideRNAs reached insertion rates between 69.0% and 78.1% 
(Shen et al., 2014). 
 The mutagenic and HDR rates with CRISPR-Cas9 match those of ZFNs and 
TALENs (Kim & Kim, 2014). A study comparing the efficiency of TALENs and 
CRISPR-Cas9 showed that CRISPR-Cas9 indel mutation rates ranged between 42% and 
100% while TALENs was about 33% (Auer & Del Bene, 2014).  A different study 
recorded mutagenesis rates of 11% for TALENs and 76% for CRISPR-Cas9 for the same 
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gene (Veres et al., 2014).  Knock-in approaches for both TALENs and CRISPR-Cas9 
have been reported as about the same—about 10.3% for TALENs and 8.3% for CRISPR-
Cas9 in one report (Auer & Del Bene, 2014). 
 Table 1 summarizes the many cell types and organisms that CRISPR-Cas9 has 
been used in as presented here. 
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Multiplexing 
 The CRISPR-Cas9 system is capable of multiplexing (Liu et al., 2014).   With 
multiple guideRNA targeting different sites and one Cas9 protein, multiple sites can be 
altered at the same times (Liu et al., 2014).  This is useful when one guideRNA is not 
enough to disrupt a gene (Auer & Del Bene, 2014) or when modifying two or more genes 
at the same time (Zhou et al., 2014).  Using two different guideRNAs to target the same 
gene has been shown to increase mutagenic frequencies (Zhou et al., 2014).  On the other 
hand, targeting more than one gene at the same time is also useful because it can decrease 
the time and money required to produce animal models with different mutations (Zhou et 
al., 2014).  Multiplexing offers a unique ability of CRISPR-Cas9 that has not been 
successfully utilized using ZFNs or TALENs due to the complexity required to design a 
protein for each targeted gene and the variable efficacy at each gene (Liu et al., 2014) 
 Multiplexing with CRISPR-Cas9 was performed shortly after the system was first 
established for use in eukaryotes (Liu et al., 2014).  On of the first multiplexing 
experiments was completed in mice with two guideRNAs targeting the Tet1 and Tet2 
genes (Wang et al., 2013).  The two guideRNAs were co-injected with Cas9 to yield bi-
allelic mutations of both genes at 80% efficiency (Wang et al., 2013).  A similar 
experiment in rats resulted in bi-allelic mutagenesis of three different genes at a rate of 
60% (Li, Teng, Li, & Zhou, 2013).  As many as six genes have been targeted at one time 
with ten guideRNAs, resulting in multiplexed gene alteration (Liu et al., 2014). 
 Multiplexing with CRISPR-Cas9 was also used to generate mouse models with 
mutations in multiple immune response genes (Zhou et al., 2014).  In an experiment, five 
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different guideRNA were injected with Cas9 into 9 mice.  The results showed that 22.2% 
had four mutations, 33.4% had three mutations, and 44.4% had two mutations (Zhou et 
al., 2014).  No mice had five different genes altered.  The multiplexing efficiency 
increased to 85% when multiple guideRNA targeting the same genes were used at the 
same time (Zhou et al., 2014).  Multiplexed editing has also shown heritability (Ma et al., 
2014).  In an experiment, researchers were able to alter four genes simultaneously with 
four different guideRNA.  Offspring genomes were analyzed and recorded the same 
mutations as the parents (Ma et al., 2014). 
 A summary of data from multiplexing experiments is displayed in Table 2. 
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Table 2.  Data from experiments using the CRISPR-Cas9 system for multiplex gene 
editing 
Cell type/ 
Organism 
Data Conclusion Source 
Mouse - Multiplex mutagenesis 
frequency of 85% for two 
different genes 
The Tet1 and Tet2 
genes can be altered 
simultaneously with 
the CRISPR-Cas9 
system 
(Wang et al., 
2013) 
Rat - Multiplex mutagenesis 
frequency of 60% for 
three different genes 
The CRIPSR-Cas9 
system is capable of 
altering three genes at 
the same time 
(Li et al., 2013) 
Bombyx mori - Used ten guideRNA to 
target six different genes 
at the same time 
The CRISPR-Cas9 
system can be used to 
disrupt six different 
genes simultaneously 
(Liu et al., 2014) 
Mouse 
- Multiplex efficiency of 
two genes was 44.4% -­‐	  Using	  two	  guideRNA	  for	  the	  same	  genes	  increased	  multiplexing	  efficiency	  to	  85%	  
Addition of guideRNA 
targeting the same 
gene can increase 
multiplexed mutagenic 
frequencies 
(Zhou et al., 
2014) 
Rat - Altered four different 
genes at the same time 
with a frequency of 73.3% -­‐	  The	  same	  genetic	  mutations	  were	  detected	  in	  offspring	  
Multiplexed 
mutagenesis with 
CRISPR-Cas9 is 
heritable 
(Ma et al., 2014) 
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Gene Regulation 
 In addition to multiplexing, gene regulation is another characteristic of CRISPR-
Cas9 systems that has not been demonstrated with either ZFNs or TALENs.  The ability 
to regulate genes is an important ability of the system because there are many diseases 
that result from too much or too little production of a protein.  Using the dCas9 protein, 
scientists can activate or repress transcription of a gene (Gilbert et al., 2013).  One way 
they have achieved gene activation is by fusing a dCas9 protein to a transcription 
activator domain, VP64, and used guideRNA that targeted a gene promoter (J. Hu et al., 
2014).  Other transcription activator domains, VP48 and VP160, have been used in 
human HeLa cells, HEK293 T cells and mouse embryo cells to activate both reporter and 
endogenous genes (Cheng et al., 2013).  Improvements to this technique have even been 
made.  In an experiment, gene activation showed six fold improvement in an experiment 
using three different proximal guideRNA targeting the same gene promoter (Cheng et al., 
2013). 
  Gene repression is also possible through dCas9 fused to KRAB, a transcription 
repressor domain, or dCas9 alone.  In an experiment using guideRNAs targeting the 
CD71 and CXCR4 genes, both dCas9 and dCas9-KRAB were able to repress expression 
of the genes by 60% to 80% (Gilbert et al., 2013).  A different study used dCas9 alone to 
sterically block binding or elongation of RNA polymerase to disrupt transcription of 
miRNA (microRNA) (Yicheng Zhao et al., 2014).  The miRNA genes miR-21 and miR-
30a were targeted with specific guideRNA, which directed dCas9 to the sites of 
transcription and repress miRNA expression (Yicheng Zhao et al., 2014). 
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Off-Target Effects  
  As presented above, there are a number of articles reporting the high efficiency 
of the CRISPR-Cas9 system to create DSBs and induce either mutagenesis or gene 
knock-in.  Off-target activity of the Cas9 protein and guideRNA has also been 
investigated.  Many articles report high system efficiency with low off-target effects (Fu, 
Sander, Reyon, Cascio, & Joung, 2014; Hruscha et al., 2013).  For example, a zebrafish 
experiment showed high gene knock-in efficiencies and reported low off-target mutations 
rates between 1.1% and 2.5%.  These low off-target mutation rates conferred system 
specificity (Hruscha et al., 2013).  The results of this experiment, however, only looked at 
potential off-target sites with high homology to the target DNA sequence not the entire 
genome (Hruscha et al., 2013).  Another researcher performed whole-genome sequencing 
to assess the amount of off-target mutagenesis that occurs throughout the entire DNA 
sequence of human pluripotent stem cells (Veres et al., 2014).  The article reported 28 
off-target indels, only one of which was in a coding sequence of the gene (Veres et al., 
2014).  Contrary to previous reports citing mismatches between guideRNA and target 
DNA reaching six nucleotides, the authors found no off-target mismatches occurred more 
than would occur by chance (Veres et al., 2014).  From the results, the researchers 
concluded that CRISPR-Cas9 system use in human pluripotent stem cells was a highly 
efficient and specific tool for disease modeling in addition to other applications (Veres et 
al., 2014). 
 Other studies have found high incidences of off-target effects induced by the 
CRISPR-Cas9 system.  An article in 2013 described an experiment using human cells in 
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which mismatches between target DNA and guideRNA of one or two nucleotides 
resulted in off-target mutations for every four in six tested guideRNA .  The experimental 
results showed that off-target mutagenesis frequencies were sometimes higher than on 
target mutagenesis for some guideRNA.  Additionally, authors observed that mismatches 
at the 5’ end of the guideRNA sequence resulted in more DNA interferences than 
mismatches at the 3’ end (Fu et al., 2013). These outcomes left the authors wondering 
about the potential applicability of the CRISPR-Cas9 system in both research and 
therapeutics (Fu et al., 2013). 
 Another paper proposed that off-target activity results when a DNA bulge or RNA 
bulge occur between the guideRNA and target DNA sequences.  A DNA bulge occurs 
where there is an insertion in the DNA sequence compared to the RNA sequence (Figure 
8A) and an RNA bulge occurs when there is a deletion in the DNA sequence compared to 
the RNA sequence (Figure 8B) (Lin et al., 2014).   In the article, the authors show that the 
CRISPR-Cas9 system used in HEK 293 T cells can cleave DNA at these sites and allows 
bulges that are 1 to 5 nucleotides in size.  Another finding was that bulges closer to the 
PAM sequence were not tolerated but bulges further from PAM could result in cleavage 
(Lin et al., 2014).  Further investigation using paired Cas9 nickases variants to induce a 
single-stranded break on each DNA strand resulted in less off-target activity but only 
when both guide RNAs induced two nicks next to one another almost simultaneously 
(Lin et al., 2014).  It was concluded that the guideRNA design is important to reduce off-
target effects (Lin et al., 2014).     
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Figure 8.  Off-target activity with RNA and DNA bulges.  A) DNA bulges are 
insertions in the target DNA sequences relative to the guideRNA sequence.  B) RNA 
bulges are deletions in the target DNA sequence relative to the guideRNA sequence.  
Both occurrences can result in off-target Cas9 binding.  Figure adapted from (Lin et al., 
2014).  
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 Further studies have been performed to characterize Cas9 binding to off-target 
sites in the genome.  In one study, researchers found that Cas9 and sgRNA concentrations 
correlated with the frequency of off-target effects.  The experimental results showed that 
off-target effects could be reduced by decreasing the amount of Cas9 and guideRNA 
injected into HEK 293T and 293FT cells (Hsu et al., 2013).  Similarly, studies have 
shown that reducing the amount of time Cas9 is expressed can also decrease chances of 
off-target effects (Waaijers & Boxem, 2014).  Another report found that off-target 
binding sites had almost no mismatches at the PAM-proximal region but could have up to 
ten mismatches at the PAM-distal region of the guideRNA (Kuscu, Arslan, Singh, 
Thorpe, & Adli, 2014).  Findings in this studied paralleled findings from the previous 
study that showed mismatches between target DNA and guide DNA were not tolerated in 
the PAM-proximal region (region closest to the PAM sequence) but were tolerated in the 
PAM-distal region (Kuscu et al., 2014).  Further characterization was done on the PAM 
sequence itself at off-target sites.  The type II CRISPR-Cas9 system uses and NRG PAM 
sequence, where N is A, C, T, or G nucleotide and R is either G or A.  In an analysis of 
PAM, it was found that over 90% of off-target binding sites, had a G instead of an A at 
the R position of NRG PAM (Kuscu et al., 2014).    
 Characterization of dCas9 binding sites was also performed.  It was found that 
dCas9 engages with on target binding sites more than off-target sites.  Similarly to WT 
(wild-type) Cas9, the PAM-proximal region is also more important for the specificity of 
dCas9 binding to target DNA (Kuscu et al., 2014).  Additionally, the study showed the 
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dCas9 binds more frequently to regions of the genome where chromatin is in a more open 
conformation and at promoters, 5’-untranslated regions and exons (Kuscu et al., 2014).   
 Several strategies have been used to reduce Cas9 off-target binding and cleavage.  
One strategy is to use tru-gRNA (truncated guideRNAs).  An experiment was performed 
to test the efficiencies of guideRNAs that had 18, 17, or 16 nucleotides of 
complementarity to target DNA  (Fu et al., 2014).  The results indicated that 17 is the 
minimum number of complementary nucleotides required for efficient Cas9 activity.  
Tru-gRNAs of 17 and 18 nucleotides showed high efficiency in both initiating targeted 
mutagenesis and homology directed repair as well as higher specificity (Fu et al., 2014).  
In some cases, off-target effects were so reduced that the specificity of the guideRNA 
increased by 5,000 fold (Fu et al., 2014).  Alternatively, studies have shown that 
increasing the length of the guideRNA does not improve specificity (Ran et al., 2013). 
 Another approach to reduce off-target effects is to use paired Cas9 nickases 
(Cas9n), which was mentioned earlier.  This method involves two offset guideRNAs that 
are complementary with the two DNA strands of the target site in combination with 
Cas9n (Ran et al., 2013).  If a nickase was directed to one strand, a single-strand break 
would result and would be mostly repaired through a base excision repair (BER) pathway 
that is highly precise.  Using two nickases directed to the same site allows the formation 
of a DSB (Figure 7A) (Ran et al., 2013).   
 A study revealed that using paired nickases can induce DSB and NHEJ or HDR at 
similar rates as WT Cas9 and with greater specificity (Ran et al., 2013).  Specificity was 
shown to increase more than 100 times greater than WT Cas9 at one target site and 
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between 200 and 1,500 time greater at other gene targets (Ran et al., 2013).  Using the 
same double nickase strategy, guideRNA pairs can be engineered to produce 5’ or 3’ 
overhangs in DNA (Figure 7B, 7C) (Ran et al., 2013).  For guideRNA pairs that 
produced a 4 to 20 base pair overhang, HDR frequencies increased to values greater then 
HDR rates using WT Cas9 (Ran et al., 2013).  This double nicking strategy has also been 
used in vivo in mouse embryos with resulting 80% mutagenesis frequencies (Ran et al., 
2013). 
 FokI nucleases offer yet another option to increase specificity of the system (Tsai 
et al., 2014). FokI nucleases required dimerization before it can cut DNA.  When fused to 
dCas9, the dCas9-FokI protein can be guided by two guideRNA to a targeted site (Tsai et 
al., 2014).  In an experiment, this version of the CRISPR-Cas9 system showed mutagenic 
efficiencies reaching 40% (Tsai et al., 2014).  The same sequences targeted by a Cas9 
nickase and single guideRNA produced greater mutagenesis frequency, but multiple off-
target point mutations were discovered (Tsai et al., 2014).  However, when sequences of 
known off-target susceptibility were examined, they showed no mutagenesis (Tsai et al., 
2014). 
 A summary data from experiments examining off-target effect is outlined in Table 
3 below. 
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Therapeutic Applications  
 Despite potential off-target effects, the CRISPR-Cas9 system has already been 
used successfully in therapeutic applications.  Some researchers have used the system to 
generate animal models with human disease mutations or to study human diseases.  One 
example is a study that was done in mouse embryo cells to understand angiogenesis in 
non-small cell lung cancer (NSCLC) (S. Chen et al., 2014).  Researchers generated 
microRNA deficient tumors using CRISPR-Cas9 to knock out the Dicer 1 gene.  Dicer 1 
knock out resulted in decreased levels of FIH-1 (Factor Inhibiting HIF-1) and insufficient 
angiogenesis signaling.  Using the CRISPR-Cas9 system, researchers were able to 
investigate the role of microRNAs in NSCLC cells and conclude that microRNAs are 
required for angiogenesis (S. Chen et al., 2014). 
 In another experiment, researchers were able to generate a mouse with the same 
mutation as a human diseases, Myelodysplastic Syndrome and Acute Myeloid Leukemia 
(C. Chen et al., 2014).  Both diseases have multiple large deletion mutations of 
chromosome 7 and 7q resulting in the loss of tumor suppressor gene, MLL3 (C. Chen et 
al., 2014).  Using the CRISPR-Cas9 system, the same mutation was generated in vivo in 
mouse embryo cells so that researchers could investigate how this disease mutation 
causes chemotherapy resistance in Myelodysplastic Syndrome and Acute Myeloid 
Leukemia (C. Chen et al., 2014).   
 The CRISPR-Cas9 system has also been used to fix gene mutations.  In one 
experiment, scientist were able to correct a mutation at the cystic fibrosis transmembrane 
conductor receptor (CFTR) that causes cystic fibrosis (Schwank et al., 2013).  Using 
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epithelial organoids (three-dimensional organ-buds) from mouse and human intestinal 
stem cells from cystic fibrosis patients with a CFTR gene mutation, the CRISPR-Cas9 
system was utilized to generate cells with the correct genetic sequence (Schwank et al., 
2013).  To correct the mutation, guideRNA targeting the CFTR gene was transfected into 
cystic fibrosis organoids with a donor plasmid encoding the WT CFTR gene sequence to 
induce a site-specific DSB and HDR.  Most cells achieved heterozygous repair with only 
one allele expressing the WT knock-in (Schwank et al., 2013).  The researchers 
concluded that CRISPR-Cas9 could be used to correct a disease mutation in human cells, 
but noted that cystic fibrosis was not an ideal candidate for in vivo therapeutic application 
since cystic fibrosis involves multiple organ systems (Schwank et al., 2013).   
 Another disease the CRISPR-Cas9 system may be material in offering a possible 
treatment is HIV.  Proposed approaches include disrupting integrated proviral DNA in 
HIV infected cells or eliminating the CCR5 gene that HIV use to enter host cells 
(Manjunath, Yi, Dang, & Shankar, 2013a).  The HIV-1 provirus is regulated by an a 
promoter protein called the LTR promoter (Ebina, Misawa, Kanemura, & Koyanagi, 
2013).  A study looked at the ability of Cas9 and a guideRNA targeting HIV-1 LTR to 
disrupt LTR expression and prevent HIV expression.  Using human cells with HIV-1 
expressing GFP proteins under the control of the LTR promoter, scientists measured the 
amount of GFP expressed before and after CRISPR-Cas9 targeting of the LTR promoter 
gene.  GRP expression was reduced from 45.6% to 20.0% (Ebina et al., 2013).  When the 
cells were co-transfected with guideRNA and Cas9 multiple times the number of GFP 
expressing cells went from 40.8% to 2.1% (Ebina et al., 2013).  These results exhibited 
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that the Cas9 protein was able to cleave and disrupt the LTR gene in HIV infected 
HEK293T cells (Ebina et al., 2013).   
 The experiment also investigated the ability of CRIPSR-Cas9 to disrupt latent 
HIV viruses.  Using a guideRNA targeting the TAR (trans-activation response element) 
gene, GFP expression was reduced from 92.56% to 68.78% in c5 cells and from 98.48% 
to 66.95% in c19 cells (Ebina et al., 2013).  Again, after multiple Cas9/guideRNA 
exposures, the percent of re-activating latently infected HIV cells showed a large 
response, decreasing from 98.7% to 35.5% (Ebina et al., 2013).  Researchers even 
showed that the HIV provirus can be removed from a host genome (Ebina et al., 2013).  
The authors of the study noted several steps that need to be taken before CRISPR-Cas9 
can be used as HIV treatment including finding a proper delivery system and minimizing 
any potential off-target effects (Ebina et al., 2013).   
 A more recent HIV study used an LTR-directed guideRNA to eliminate the HIV 
genome and prevent re-activation of the virus in a specific and efficient manner (W. Hu 
et al., 2014).  Using two different guideRNAs to target the LTR gene, researchers were 
able to diminish off-target effects and increased efficiency (W. Hu et al., 2014).  A novel 
finding in this study was that the addition of Cas9 and guideRNA to a cell before HIV 
infection still results in removal of the viral DNA before it integrates into the host 
genome (W. Hu et al., 2014).   This finding suggests that HIV vaccination may be 
possible through CRISPR-Cas9 for individuals at high risk of contracting the virus (W. 
Hu et al., 2014).	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 While there are other treatment options for HIV, and there are already clinical 
trials investigating ZFN and TALEN applications in HIV gene therapy, the CRISPR-
Cas9 system still holds some advantages.  Studies with ZFN have proven costly, had low 
efficiency and raised concerns about safety (Manjunath, Yi, Dang, & Shankar, 2013b).  
One attempt using TALENs showed improved results with lower off-target effects, 
however deliver of the large size protein proved too difficult a hurdle to overcome and no 
others have tried further studies (Manjunath et al., 2013b).  So far, the CRISPR-Cas9 
system has shown greater disruption of HIV associated genes, like CCR5, than both 
ZFNs and TALENs (Manjunath et al., 2013b).	  
 In other approaches, the CRISPR-Cas9 system has been harnessed to induce a 
mutation for therapeutic effects.  One example of this is involves the PCSK9 gene.  The 
PCSK9 gene has naturally occurring mutations that result in a functional loss of the gene 
(Ding et al., 2014).  In individuals with this loss-of function mutation, blood low-density 
lipoprotein cholesterol (LDL-C) levels are decreased and cardiovascular disease risk is 
reduced (Ding et al., 2014).  In an experiment, scientists used the CRISPR-Cas9 to create 
a loss-of-function PCSK9 gene mutation in vivo in mice to see if LDL-C levels were 
effects.  After the mice were given an adenovirus expressing Cas9 and PCSK9-targeted 
guideRNA directed to the liver, the results revealed a 35% – 40% decrease in blood 
cholesterol levels (Ding et al., 2014).  The CRISPR-Cas9 system produced over 50%	  
mutagenesis rates at the PCSK9 locus most frequently through 1 basepair insertion and a 
2 basepair deletion (Ding et al., 2014).  Additionally, there were no off-target mutations 
detected at ten examined sequences (Ding et al., 2014).  Researchers noted that the 
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CRISPR-Cas9 system could be used in the future as a one-time vaccine to irreversibly 
reduce plasma cholesterol levels (Ding et al., 2014). 
 The CRISPR-Cas9 system has also been used in vivo to correct a gene mutation in 
an adult mouse model (Yin et al., 2014).  Hereditary tyrosinemia type I (HTI) is a fatal 
genetic disease effecting the tyrosine catabolic pathway that is caused by a mutation of 
the fumarylacetoacetate hydrolase (FAH) gene (Yin et al., 2014).  The mutations is a G 
! A point mutation of the exon resulting in a shortened and destabilized FAH protein 
(Yin et al., 2014).  HTI disease model mice have a phenotype consisting of extreme 
weight loss.  When HTI mice were given plasmids expressing Cas9 and guideRNA 
targeting FAH locus and a donor DNA, the preliminary results showed 1 in 250 liver 
cells produced the FAH protein and a reversal of the weight loss phenotype (Yin et al., 
2014).  Four potential off-target sites were sequenced and a less than 0.3% mutagenesis 
rate was identified (Yin et al., 2014).	  
 A summary of experiments using the CRISPR-Cas9 system for therapeutic 
approaches is outlined in Table 4 below.	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Delivery 	   As with ZFNs and TALENs, one challenge of applying the CRISPR-Cas9 system 
is determining a proper delivery method to ensure the Cas9 protein and guideRNA enter a 
cell (Manjunath et al., 2013b).  A number of delivery approaches have been used for in 
vivo and in vitro applications in humans and animals.  These include: electroporation, 
microinjection, lentiviral vectors, adenoviral vectors and adeno-associated vectors 
(Figure 10.	  
 Electroporation works by placing cells in a conductive solution enclosed in an 
electrical circuit.  An electrical pulse is then applied to the solution and the electrical 
potential allows pores to form in the cell membrane, which RNA can then pass through 
(“Electroporation | Life Technologies,” n.d.).  Electroporation has been used in vitro in 
Toxoplasma gondii cells (Shen et al., 2014), mice cells (Gennequin, Otte, & Zimmer, 
2013), and cynomolgus monkey cells (Niu et al., 2014) to deliver Cas9 and guideRNA.  	  
 Microinjection is another delivery method used to get the CRISPR-Cas9 
components into cells (Horii et al., 2014).  This mechanism allows Cas9 mRNA and 
guideRNA administration to a cell cytoplasm or pronucleus by direct injection (Horii et 
al., 2014).  Microinjection has been utilized in C. elegans (Tzur et al., 2013), pigs (Hai, 
Teng, Guo, Li, & Zhou, 2014), axolotl (Flowers, Timberlake, Mclean, Monaghan, & 
Crews, 2014), and mice (Horii et al., 2014) among other organisms.  	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Figure 10.  Delivery methods of DNA and RNA. 1A) A cell is surrounded by a solution 
with particles that cannot cross the cell membrane.  1B) An electrical current allows 
pores to form in the membrane so the particles can cross into the cytoplasm.  1C) 
Particles have entered the cell and the pores disappear once the electrical current stops 
(“Electroporation | Life Technologies,” n.d.).  2) A holding pipet (A) holds a cell (B) 
while a needle (C) injects DNA or RNA into the cell nucleus or cytoplasm (Horii et al., 
2014). 3A) A viral vector enters the cell as an endosome. 3B) The DNA to be expressed 
enters the nucleus. 3C) Transcription and translation occur, producing a protein 
(Benihoud, 1999).	  
A" B" C"
1)#
2)#
A" B"
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mRNA%
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Since guideRNA exerts its effects in the nucleus and Cas9 mRNA in the cytoplasm, it 
would be beneficial to microinject each into its respective location, however this task is 
not a realistic approach (Horii et al., 2014).  An experiment was done to determine the 
best location for microinjection of both Cas9 mRNA or DNA and guideRNA (Horii et al., 
2014).  The results showed that the highest mutagenesis frequencies occurred when Cas9 
mRNA and guideRNA were injected into the cytoplasm of a mouse embryo cell (Horii et 
al., 2014).	  
 Viral vectors offer another approach for delivering genetic material to a cell 
(Maggio et al., 2014).  Although the Cas9 protein itself is large, viral vectors carrying 
Cas9 mRNA offer a solution for in vivo delivery (Cooray, Howe, & Thrasher, 2012). 
Lentiviruses are one type of viral vector that can integrate genetic material into non-
dividing cells (Cooray et al., 2012).  This technique has been used in both mouse and 
human cells (Gilbert et al., 2013; Prashant Mali, Aach, et al., 2013; Malina et al., 2013).  
Other viral vector alternatives for gene delivery are adenoviruses (AdV) (Benihoud, 
1999) and adeno-associated viruses (AAV) (Khan, Hirata, & Russell, 2011).  AdV 
vectors have been used to deliver CRISPR-Cas9 components to human cells (Maggio et 
al., 2014) and AAV vectors have been used in mouse cells (Ding et al., 2014). 	  
 Table 5 summarizes the delivery methods used in CRISPR-Cas9 experiments and 
the organisms in which they have been applied.	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Table	  5.	  	  Methods	  used	  to	  deliver	  Cas9	  and	  guideRNA	  to	  cells	  
Delivery Method Cell type/ 
Organism 
In vivo/ 
in vitro 
Sources 
Electroporation Mice 
Cynomolgus 
monkey 
T. gondii 
S. cerevisiae 
In vitro (DiCarlo et al., 2013; 
Gennequin et al., 2013; Niu et 
al., 2014; Shen et al., 2014)  
Microinjection Axolotl 
Rat 
C. elegans 
Pig 
Mouse 
Zebrafish 
Drosophila 
Medaka 
D. magna 
B. morii 
X. tropicalis 
In vivo 
In vitro 
(Ansai & Kinoshita, 2014; 
Bassett, Tibbit, Ponting, & Liu, 
2013; Flowers et al., 2014; Guo 
et al., 2014; Hai et al., 2014; 
Horii et al., 2014; Hwang et al., 
2013b; Liu et al., 2014; Ma et 
al., 2014; Nakanishi, Kato, 
Matsuura, & Watanabe, 2014; 
Tzur et al., 2013) 
Lentivirus Mouse 
Human HEK293 
T cells 
In vivo 
In vitro 
(Gilbert et al., 2013; Prashant 
Mali, Aach, et al., 2013; Malina 
et al., 2013) 
Adenovirus Human HEK293 
T cells 
In vitro (Bi et al., 2014; Khan et al., 
2011; Maggio et al., 2014) 
Adeno-associated 
virus 
Mouse  In vivo  
In vitro 
(Ding et al., 2014) 	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DISCUSSION  
 Over the past couple of years, the number of publications published on the 
CRIPSR-Cas9 technology has reached over 900, an unprecedented number in the world 
of biotechnology.  What the papers and the data say is that the CRISPR-Cas9 system has 
shown great efficiency and efficacy in a vast array of organisms as discussed here.  The 
papers show that the system has many advantages over other gene editing systems that 
are already being used in the clinic.  Some of these advantages include its minimal 
system components, its ability to alter multiple genes at the same time, and its diverse 
ability to induce NHEJ in addition to HDR and gene regulation.  These characteristics 
make CRISPR-Cas9 an inexpensive, simpler and faster system to use and engineer as 
only the guideRNA must be engineered before use.  	  
 In regards to minimizing CRISPR-Cas9 off-target activity, a number of 
approaches have been used including: truncated guideRNAs, double nickases, and lower 
concentrations of guideRNA and Cas9 mRNA.  Despite the majority of articles reporting 
low off-target effects using the system, there are some contradictory results showing high 
off-target activity.  Since there is such variability in the number of off-target binding and 
cleavage events for different guideRNA, cell types and target genes, there is further 
investigation in the molecular mechanism of Cas9 binding and cleavage required.  Based 
on the evidence presented, it is expected that guideRNAs can be engineered to prevent 
off-target effects.  Cas9 variants may offer additional specificity.  The Cas9 nickase 
presented above and FokI-paired dCas9 mechanisms offer additional solutions.  	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 Using the CRISPR-Cas9 system for therapeutic purposes seems like the natural 
next step for utilizing the technology as multiple experiments have already shown its 
applicability.  Based on experiments presented above, it appears that correcting disease 
mutations using CRISPR-Cas9 is not a matter of determining if it can be done, but 
depends on when certain aspects of the system have been tweaked and studied enough for 
use in vivo in humans.  Before an in vivo approach can be utilized, more research is 
required to determine how to deliver Cas9 mRNA and guideRNA to the appropriate 
target cells and ensure that they can gain entrance into cell of interest and only cells of 
interest.	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